Stable 10.6% Margin At Hangzhou Jiuyuan Genetic Biopharmaceutical Reinforces Bullish Valuation Narratives

Simply Wall St.

Apr 01

Hangzhou Jiuyuan Genetic Biopharmaceutical (SEHK:2566) has put fresh FY 2025 numbers on the table, with first half revenue of C¥638.8 million and basic EPS of C¥0.37 setting the tone for how the year ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2624548043"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624548043\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624548043?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-04-01 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624548043","market":"sg","top_or_hot":-1,"title":"Stable 10.6% Margin At Hangzhou Jiuyuan Genetic Biopharmaceutical Reinforces Bullish Valuation Narratives","media":"Simply Wall St.","content":"<div>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical (SEHK:2566) has put fresh FY 2025 numbers on the table, with first half revenue of C¥638.8 million and basic EPS of C¥0.37 setting the tone for how the year ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2566/hangzhou-jiuyuan-genetic-biopharmaceutical-shares/news/stable-106-margin-at-hangzhou-jiuyuan-genetic-biopharmaceuti\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stable 10.6% Margin At Hangzhou Jiuyuan Genetic Biopharmaceutical Reinforces Bullish Valuation Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStable 10.6% Margin At Hangzhou Jiuyuan Genetic Biopharmaceutical Reinforces Bullish Valuation Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-01 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2566/hangzhou-jiuyuan-genetic-biopharmaceutical-shares/news/stable-106-margin-at-hangzhou-jiuyuan-genetic-biopharmaceuti><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical (SEHK:2566) has put fresh FY 2025 numbers on the table, with first half revenue of C¥638.8 million and basic EPS of C¥0.37 setting the tone for how the year ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2566/hangzhou-jiuyuan-genetic-biopharmaceutical-shares/news/stable-106-margin-at-hangzhou-jiuyuan-genetic-biopharmaceuti\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2566/hangzhou-jiuyuan-genetic-biopharmaceutical-shares/news/stable-106-margin-at-hangzhou-jiuyuan-genetic-biopharmaceuti","article_id":"2624548043","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2566/hangzhou-jiuyuan-genetic-biopharmaceutical-shares/news/stable-106-margin-at-hangzhou-jiuyuan-genetic-biopharmaceuti","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624548043","pubTimestamp":1775050139,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical (SEHK:2566) has put fresh FY 2025 numbers on the table, with first half revenue of C¥638.8 million and basic EPS of C¥0.37 setting the tone for how the year is shaping up. Over recent halves the company has seen revenue move from C¥702.4 million and EPS of C¥0.53 in 1H 2024 to C¥666.8 million and EPS of C¥0.16 in 2H 2024, giving investors a clear view of how the current run rate compares with recent history. With trailing 12 month net profit margins...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BK1161":"生物科技","BLSG":"2倍做多BLSH ETF-Leverage Shares","BLSX":"Tradr 2X Long BLSH Daily ETF","02566":"九源基因"},"translate_title":"杭州九源基因生物制药10.6%的稳定利润率强化了看涨的估值叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1.97,"BLSX":0.6,"BLSG":0.6},"content_text":"Hangzhou Jiuyuan Genetic Biopharmaceutical (SEHK:2566) has put fresh FY 2025 numbers on the table, with first half revenue of C¥638.8 million and basic EPS of C¥0.37 setting the tone for how the year is shaping up. Over recent halves the company has seen revenue move from C¥702.4 million and EPS of C¥0.53 in 1H 2024 to C¥666.8 million and EPS of C¥0.16 in 2H 2024, giving investors a clear view of how the current run rate compares with recent history. With trailing 12 month net profit margins running at 10.6%, the latest release offers a results set where profitability holds the spotlight for your assessment of earnings quality. See our full analysis for Hangzhou Jiuyuan Genetic Biopharmaceutical. With the headline figures in place, the next step is to see how these results line up with the prevailing stories about growth, risk and profitability that investors have been following. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:2566 Revenue & Expenses Breakdown as at Apr 2026 Advertisement10.6% margin holds against earnings bumpiness  Trailing 12 month net profit margin of 10.6% compares with 10.1% a year earlier, while the most recent trailing net income of C¥138.4 million sits close to the C¥138.6 million level reported a year before on a trailing basis. What stands out for a bullish view is the mix of a 10.6% margin and a five year earnings growth rate of 8.7% a year, set against the most recent year of negative earnings growth compared with that longer trend.\n     Supporters can point to margins holding above 10% and trailing net income in the C¥138 million range as evidence that the business is still generating profits even as yearly growth has been uneven. On the other hand, the shift from that 8.7% multi year growth rate to negative earnings growth in the latest year challenges any simple bullish story that relies only on the long term trend.    Curious how this mix of steady margins and uneven growth fits into the wider story investors are telling around the stock right now? 📊 Read the what the Community is saying about Hangzhou Jiuyuan Genetic Biopharmaceutical. Earnings run rate softens across recent halves  Net income for the last three reported halves moved from C¥105.3 million in 1H 2024 to C¥33.3 million in 2H 2024, then to C¥90.2 million in 1H 2025, which pairs with basic EPS going from C¥0.53 to C¥0.16 and then C¥0.37 across those same periods. Critics of a bullish stance often focus on this pattern of EPS and net income across halves, because it contrasts with the longer term 8.7% annual earnings growth figure.\n     The step down from 1H 2024 EPS of C¥0.53 to 2H 2024 EPS of C¥0.16, followed by 1H 2025 EPS of C¥0.37, shows that earnings per share have not followed a straight line that would match the five year growth rate. The trailing 12 month EPS of C¥0.54 by 1H 2025, set against that pattern, underlines that short term fluctuations can be large even when the multi year growth statistic looks smooth.    10.4x P/E and DCF fair value gap  The shares trade on a trailing P/E of 10.4x at a price of HK$6.77, compared with an industry average P/E of 38x and peer average of 55.3x, while a DCF fair value of HK$8.27 sits about 18.1% above the current share price. Supporters of a bullish angle often highlight this valuation gap, but the same numbers also have to be read alongside the recent negative earnings growth versus the five year 8.7% compound rate.\n     The combination of a 10.4x P/E and DCF fair value of HK$8.27 relative to a HK$6.77 share price is often used to support a value focused bullish case that views the trailing profit stream as under recognised. At the same time, the most recent year of negative earnings growth compared with the multi year record means the low multiple and DCF gap are being judged against a period where growth has not followed the prior pattern.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Hangzhou Jiuyuan Genetic Biopharmaceutical's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. Given the mix of steady margins, recent earnings softness and valuation signals, it helps to check the underlying data yourself and not rely only on the headline story. If you want to see what is driving the optimism around the company, take a closer look at the 1 key reward See What Else Is Out There The recent pattern of uneven EPS and net income across halves, together with a year of earnings contraction versus the 8.7% multi year trend, raises consistency questions. If this bumpiness in profits makes you want steadier prospects, check out the 269 resilient stocks with low risk scores to quickly spot companies where earnings and risk profiles look more controlled.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hangzhou Jiuyuan Genetic Biopharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}